COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

被引：0
|
作者：
Woods, B. [1 ]
Thompson, J. [1 ]
Barcena, L. [1 ]
Liu, Y. [2 ]
Huang, H. [2 ]
Martinez, C. [3 ]
机构：
[1] Oxford Outcomes, Oxford, England
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Inst Hematol & Oncol, Barcelona, Spain
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1728
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A509 / A509
页数：1
相关论文
共 50 条
  • [1] COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA AGAINST PUBLISHED OUTCOME DATA IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
    Thompson, J.
    Barcena, L.
    Woods, B.
    Liu, Y.
    Huang, H.
    Hatton, C.
    HAEMATOLOGICA, 2012, 97 : 85 - 85
  • [2] RELAPSED OR REFRACTORY (REL/REF) HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) - A RARE CANCER WITH NO STANDARD OF CARE
    Eaton, J.
    Baculea, S.
    Liu, Y.
    Huang, H.
    Hatton, C.
    HAEMATOLOGICA, 2012, 97 : 565 - 565
  • [3] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland
    Parker, Christopher
    Woods, Beth
    Eaton, James
    Ma, Esprit
    Selby, Ross
    Benson, Eugene
    Engstrom, Andreas
    Sajosi, Peter
    Briggs, Andrew
    Bonthapally, Vijayveer
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 8 - 18
  • [4] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
    Bonthapally, Vijayveer
    Wu, Eric
    Macalalad, Alexander
    Yang, Hongbo
    Shonukan, Oluwatoyin
    Liu, Yi
    Chi, Andy
    Huebner, Dirk
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (05) : 993 - 1001
  • [5] Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant
    Karuturi, Meghan S.
    Arai, Sally
    Chen, Robert W.
    Gopal, Ajay K.
    Feng, Lei
    Yuan, Ying
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlet, Nancy L.
    Cheson, Bruce D.
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Fanale, Michelle A.
    de Vos, Sven
    Engert, Andreas
    Illidge, Tim
    Borchmann, Peter
    Morschhauser, Franck
    Horning, Sandra J.
    Younes, Anas
    BLOOD, 2012, 120 (21)
  • [6] Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis
    Bonthapally, Vijayveer
    Yang, Hongbo
    Ayyagari, Rajeev
    Tan, Ruo-Ding
    Cai, Sean
    Wu, Eric
    Gautam, Ashish
    Chi, Andy
    Huebner, Dirk
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (07) : 1377 - 1389
  • [7] Brentuximab vedotin (BV) consolidation post-autologous stem cell transplant (ASCT) in patients (pts) with Hodgkin lymphoma (HL) at risk of residual disease: Number needed to treat (NNT) analysis
    Gautam, Ashish
    Huebner, Dirk
    Zhu, Yanyan
    Ma, Esprit
    Lee, Shih-Yuan
    Zagadailov, Erin
    Teasell, Jeremy
    Richhariya, Akshara
    Bonthapally, Vijayveer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [8] Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
    Marouf, Amira
    Cottereau, Anne Segolene
    Kanoun, Salim
    Deschamps, Paul
    Meignan, Michel
    Franchi, Patricia
    Sibon, David
    Antoine, Clara
    Gastinne, Thomas
    Borel, Cecile
    Hammoud, Mohammad
    Sicard, Guillaume
    Gille, Romane
    Cavalieri, Doriane
    Stamatoullas, Aspasia
    Filliatre-Clement, Lauriane
    Lazarovici, Julien
    Chauchet, Adrien
    Fornecker, Luc-Matthieu
    Amorin, Sandy
    Rocquet, Mathieu
    Raus, Nicole
    Burroni, Barbara
    Rubio, Marie Therese
    Bouscary, Didier
    Quittet, Philippe
    Casasnovas, Rene Olivier
    Brice, Pauline
    Ghesquieres, Herve
    Tamburini, Jerome
    Deau, Benedicte
    HAEMATOLOGICA, 2022, 107 (07) : 1681 - 1686
  • [9] Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
    Kaloyannidis, Panayotis
    Hertzberg, Mark
    Webb, Kate
    Zomas, Athanasios
    Schrover, Rudolf
    Hurst, Michael
    Jacob, Ian
    Nikoglou, Thalia
    Connors, Joseph M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 540 - 549
  • [10] BRENTUXIMAB VEDOTIN (BV) IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (RRHL): A UK AND GERMANY RETROSPECTIVE STUDY
    Broeckelmann, P. J.
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Dalal, M. R.
    HAEMATOLOGICA, 2016, 101 : 98 - 98
12345